# Study of the Safety and Efficacy of DS010 in Patients With Cancer Cachexia

> **NCT07530666** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Dartsbio Pharmaceuticals Ltd.** · enrollment: 58 (estimated)

## Conditions studied

- Cancer
- Cachexia

## Interventions

- **DRUG:** DS010 injection
- **DRUG:** DS010 injection
- **DRUG:** DS010 injection
- **DRUG:** DS010 injection
- **DRUG:** DS010 injection
- **DRUG:** DS010 injection
- **DRUG:** DS010 injection
- **DRUG:** DS010 injection
- **DRUG:** DS010 injection
- **DRUG:** DS010 injection

## Key facts

- **NCT ID:** NCT07530666
- **Lead sponsor:** Dartsbio Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2027-10-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07530666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07530666, "Study of the Safety and Efficacy of DS010 in Patients With Cancer Cachexia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07530666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*